Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non–muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy

Published:February 02, 2017DOI:


      To report long-term follow-up results of a phase II trial of salvage intravesical nanoparticle albumin-bound (nab)-paclitaxel for patients with recurrent non–muscle-invasive bladder cancer after previous intravesical bacillus Calmette-Guérin (BCG) therapy.


      This was a phase II trial investigating the use of intravesical nab-paclitaxel in patients with recurrent Tis, Ta, and T1 urothelial carcinoma who failed at least 1 prior induction course of intravesical BCG. Patients received 500 mg/100 mL of nab-paclitaxel in 6 weekly intravesical instillations. Complete responders were offered full-dose maintenance for 6 months. Overall survival, recurrence-free survival, cystectomy-free survival, and cancer-specific survival were assessed via Kaplan-Meier analysis.


      A total of 28 patients were enrolled with a median follow-up of 41 months (range 5-76). There were 22 men and 6 women with a median age of 79 (range 36-93), and the median number of prior intravesical therapies was 2. Twenty-one of the 28 patients (75%) were BCG refractory. Ten of the 28 patients (36%) achieved complete response. Six of the 28 patients remain cancer free, with a recurrence-free survival rate of 18%. Five-year overall and cancer-specific survival rates were 56% and 91%, respectively. Radical cystectomy occurred in 11 of the 28 patients (39%), of whom 2 out of 11 (18%) had pT2 or greater disease.


      With a median follow-up of 41 months, 18% of this cohort treated with nab-paclitaxel was disease free. Cystectomy-free survival was 61% and bladder cancer-specific mortality was 9%. Nab-paclitaxel is a reasonable treatment option in this high-risk population.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2016.
        CA Cancer J Clin. 2016; 66: 7-30
        • Burger M.
        • Catto J.W.
        • Dalbagni G.
        • et al.
        Epidemiology and risk factors of urothelial bladder cancer.
        Eur Urol. 2013; 63: 234-241
        • Chang S.S.
        • Boorjian S.A.
        • Chou R.
        • et al.
        Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline.
        J Urol. 2016; 196: 1021-1029
        • Herr H.W.
        • Wartinger D.D.
        • Fair W.R.
        • Oettgen H.F.
        Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup.
        J Urol. 1992; 147: 1020-1023
        • Lamm D.L.
        • Blumenstein B.A.
        • Crissman J.D.
        • et al.
        Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
        J Urol. 2000; 163: 1124-1129
        • Morales A.
        Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer.
        J Urol. 1984; 132: 457-459
        • Catalona W.J.
        • Hudson M.A.
        • Gillen D.P.
        • Andriole G.L.
        • Ratliff T.L.
        Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
        J Urol. 1987; 137: 220-224
        • Hall M.C.
        • Chang S.S.
        • Dalbagni G.
        • et al.
        Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
        J Urol. 2007; 178: 2314-2330
        • Babjuk M.
        • Burger M.
        • Zigeuner R.
        • et al.
        EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
        Eur Urol. 2013; 64: 639-653
        • Bochner B.H.
        • Dalbagni G.
        • Sjoberg D.D.
        • et al.
        Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial.
        Eur Urol. 2015; 67: 1042-1050
        • Johar R.S.
        • Hayn M.H.
        • Stegemann A.P.
        • et al.
        Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.
        Eur Urol. 2013; 64: 52-57
        • Adams J.D.
        • Flora K.P.
        • Goldspiel B.R.
        • Wilson J.W.
        • Arbuck S.G.
        • Finley R.
        Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
        J Natl Cancer Inst Monogr. 1993; 15: 141-147
        • Rowinsky E.K.
        • Cazenave L.A.
        • Donehower R.C.
        Taxol: a novel investigational antimicrotubule agent.
        J Natl Cancer Inst. 1990; 82: 1247-1259
        • Sparreboom A.
        • Scripture C.D.
        • Trieu V.
        • et al.
        Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
        Clin Cancer Res. 2005; 11: 4136-4143
        • Gradishar W.J.
        • Tjulandin S.
        • Davidson N.
        • et al.
        Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
        J Clin Oncol. 2005; 23: 7794-7803
        • Von Hoff D.D.
        • Ervin T.
        • Arena F.P.
        • et al.
        Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
        N Engl J Med. 2013; 369: 1691-1703
        • Montero A.J.
        • Adams B.
        • Diaz-Montero C.M.
        • Gluck S.
        Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.
        Expert Rev Clin Pharmacol. 2011; 4: 329-334
        • McKiernan J.M.
        • Barlow L.J.
        • Laudano M.A.
        • Mann M.J.
        • Petrylak D.P.
        • Benson M.C.
        A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer.
        J Urol. 2011; 186: 448-451
        • McKiernan J.M.
        • Holder D.D.
        • Ghandour R.A.
        • et al.
        Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guerin treatment failure.
        J Urol. 2014; 192: 1633-1638
        • Kamat A.M.
        • Sylvester R.J.
        • Bohle A.
        • et al.
        Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group.
        J Clin Oncol. 2016; 34: 1935-1944
        • Skinner E.C.
        • Goldman B.
        • Sakr W.A.
        • et al.
        SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin.
        J Urol. 2013; 190: 1200-1204
        • Barlow L.J.
        • McKiernan J.M.
        • Benson M.C.
        The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience.
        World J Urol. 2009; 27: 331-335
        • Barlow L.J.
        • McKiernan J.M.
        • Benson M.C.
        Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy.
        J Urol. 2013; 189: 834-839
        • Correa A.F.
        • Theisen K.
        • Ferroni M.
        • et al.
        The role of interferon in the management of BCG refractory nonmuscle invasive bladder cancer.
        Adv Urol. 2015; 2015: 656918
        • O'Donnell M.A.
        • Krohn J.
        • DeWolf W.C.
        Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.
        J Urol. 2001; 166 (discussion 1304-1305): 1300-1304
        • Malmstrom P.U.
        • Wijkstrom H.
        • Lundholm C.
        • Wester K.
        • Busch C.
        • Norlen B.J.
        5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.
        J Urol. 1999; 161: 1124-1127
        • Nativ O.
        • Witjes J.A.
        • Hendricksen K.
        • et al.
        Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
        J Urol. 2009; 182: 1313-1317
        • Yates D.R.
        • Brausi M.A.
        • Catto J.W.
        • et al.
        Treatment options available for bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
        Eur Urol. 2012; 62: 1088-1096
        • Steinberg G.
        • Bahnson R.
        • Brosman S.
        • Middleton R.
        • Wajsman Z.
        • Wehle M.
        Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
        J Urol. 2000; 163: 761-767